• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Candidiasis - Pipeline Review, H2 2012 Product Image

Candidiasis - Pipeline Review, H2 2012

  • ID: 2245174
  • September 2012
  • 99 pages
  • Global Markets Direct

Candidiasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Candidiasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Candidiasis. Candidiasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Candidiasis.
- A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Candidiasis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Candidiasis 10
Candidiasis Therapeutics under Development by Companies 12
Candidiasis Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Candidiasis Therapeutics – Products under Development by Companies 20
Candidiasis Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Candidiasis Therapeutics Development 22
BioDelivery Sciences International, Inc. 22
Daiichi Sankyo Company, Ltd 23
Merck & Co., Inc. 24
Stiefel Laboratories, Inc. 25
iCo Therapeutics Inc. 26
Almirall, S.A. 27
Basilea Pharmaceutica Ltd. 28
MethylGene Inc 29
Pacgen Biopharmaceuticals Corporation 30
Pevion Biotech Ltd 31
Novabiotics Ltd 32
NovaDigm Therapeutics, Inc. 33
Ferrer Internacional S.A. 34
Sosei Co. Ltd. 35
Lee's Pharmaceutical Holdings Limited 36
Viamet Pharmaceuticals, Inc. 37
Pacific Beach BioSciences, Inc 38
Demegen, Inc. 39
Wellstat Vaccines, LLC 40
Candidiasis – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
isavuconazole - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PAC-113 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
amphotericin B - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
albaconazole - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
sertaconazole - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PEV-7 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LAS-41003 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MGCD-290 + Fluconazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
lipid-based amphotericin B - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
fluconazole - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Lavender Vaginal Cream - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PB-200 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Metronidazole + Miconazole - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Ketoconazole + Clindamycin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
butoconazole nitrate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
caspofungin acetate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NDV-3 Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SLP-1002 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SLP-0907 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 72
SLP-0901 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 74
Interferon gamma - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
r-MP65 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tamoxifen citrate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Nystatin + Intralipid - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
miconazole lauriad - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
VT-1161 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
D11-2040 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
P113 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ZK-004 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Candidiasis Therapeutics – Drug Profile Updates 84
Candidiasis Therapeutics – Discontinued Products 89
Candidiasis Therapeutics - Dormant Products 90
Candidiasis – Product Development Milestones 91
Featured News & Press Releases 91
Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis 91
Aug 02, 2012: MethylGene Recruits Patiens In Phase II trial Of MGCD290 92
Jul 02, 2012: Sosei Completes Phase I Study Of SO-1105 For Treatment Of Oropharyngeal Candidiasis 92
May 07, 2012: NovaDigm Therapeutics Presents Positive Safety And Immunogenicity Data In Second Phase I Study For NDV-3 Vaccine 93
Mar 08, 2012: Sosei Initiates Phase I Study Of SO-1105 In Japan 94
Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees 94
Oct 11, 2011: Pevion’s Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity 95
Sep 19, 2011: NovaDigm Presents Positive Phase I Safety And Immunogenicity Data For NDV-3 Vaccine 96
Sep 12, 2011: NovaDigm Therapeutics To Present Positive Phase I Clinical Data For NDV-3 Vaccine At ICAAC 97
Sep 12, 2011: NovaDigm Therapeutics To Present Positive Preclinical Data For NDV-3 Vaccine At ICAAC 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Tables
Number of Products Under Development for Candidiasis, H2 2012 10
Products under Development for Candidiasis – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
BioDelivery Sciences International, Inc., H2 2012 22
Daiichi Sankyo Company, Ltd, H2 2012 23
Merck & Co., Inc., H2 2012 24
Stiefel Laboratories, Inc., H2 2012 25
iCo Therapeutics Inc., H2 2012 26
Almirall, S.A., H2 2012 27
Basilea Pharmaceutica Ltd., H2 2012 28
MethylGene Inc, H2 2012 29
Pacgen Biopharmaceuticals Corporation, H2 2012 30
Pevion Biotech Ltd, H2 2012 31
Novabiotics Ltd, H2 2012 32
NovaDigm Therapeutics, Inc., H2 2012 33
Ferrer Internacional S.A., H2 2012 34
Sosei Co. Ltd., H2 2012 35
Lee's Pharmaceutical Holdings Limited, H2 2012 36
Viamet Pharmaceuticals, Inc., H2 2012 37
Pacific Beach BioSciences, Inc, H2 2012 38
Demegen, Inc., H2 2012 39
Wellstat Vaccines, LLC, H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 46
Candidiasis Therapeutics – Drug Profile Updates 84
Candidiasis Therapeutics – Discontinued Products 89
Candidiasis Therapeutics – Dormant Products 90

List of Figures
Number of Products under Development for Candidiasis, H2 2012 10
Products under Development for Candidiasis – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos